ESPID Reports and Reviews

CONTENTS
Prevention and Treatment of Bacterial Meningitis
EDITORIAL BOARD
Co-Editors: Delane Shingadiaand Irja Lutsar
Board Members
David Burgner (Melbourne, Australia) Nicole Ritz (Basel, Switzerland) Tobias Tenenbaum (Mannhein, Germany)
Luisa Galli (Rome, Italy) Ira Shah (Mumbai, India) Marc Terbruegge (Southampton, UK)
Christiana Nascimento-Carvalho Matthew Snape (Oxford, UK) Marceline van Furth (Amsterdam,
(Bahia, Brazil) George Syrogiannopoulos The Netherlands)
Ville Peltola (Turku, Finland) (Larissa, Greece) Anne Vergison (Brussels, Belgium)

Prevention and Treatment of Bacterial Meningitis in Resource

Poor Settings
Elizabeth Molyneux, FRCPCH and Jenala Njirammadzi, MBBS

T he etiology and incidence of bacterial

meningitis (BM) in resource poor set-
tings is changing. Antibiotic resistance pat-
terns have altered and empirical antibiotic
treatment options need review. Recent stud-
ies have assessed adjuvant therapies and sup-
portive care.
THE EFFECT OF VACCINES ON THE
INCIDENCE AND ETIOLOGY OF
BACTERIAL MENINGITIS
In the past decade, there have been
remarkable reductions in child mortality
driven largely by public health efforts. In HIV
endemic countries, the role out of prophylactic
cotrimoxazole and the increased availability
of antiretroviral therapy has coincided with a
reduction in the incidence of Streptococcus
pneumoniae infections. The role out of these
programs and increasing access to conjugate
vaccines for Haemophilus influenzae b (Hib),
pneumococci and Group A meningoccoci
(MenAfriVac) are changing the epidemiology
and incidence of meningitis. Hib vaccine is
Accepted for publication January 23, 2015.
From the Department of Paediatrics, College of Medi-
cine, Queen Elizabeth Central Hospital, Blantyre,
Malawi.
The authors have no conflicts of interest to disclose.
Address for correspondence: Elizabeth M. Molyneux,
FRCPCH, Department of Paediatrics, College of
Medicine, Queen Elizabeth Central Hospital, Blan-
tyre, Malawi. E-mail: emmolyneux@gmail.com.
Copyright 2015 by Wolters Kluwer Health, Inc. All
rights reserved.
ISSN: 0891-3668/15/3404-0441
DOI: 10.1097/INF.0000000000000665
part of the extended program for immunization
in 72 countries leading to a rapid reduction of
invasive Hib infections.1
Meningococcal meningitis is the most
common bacterial meningitis worldwide and
Group A was the most common epidemic-
causing meningococcus. In 2010, a conju-
gated vaccine, MenAfriVac became available
that is highly efficacious even in young chil-
dren and also increases herd immunity. By
2016, 26 African meningitis belt countries
will have immunized their most vulnerable
age groups. But there is more to be done:
serogroup A disease has decreased but sero-
groups W135 and X have caused recent out-
breaks.2,3 In the United States, the Advisory
Committee on Immunisation Practices states
that immunogenicity of meningococcal con-
jugate vaccines decreases with time, and rec-
ommends a booster dose after 5 years.4
The 13-valent pneumococcal vac-
cine, licensed in 2010, has been added
to the extended program for immuniza-
tion schedule in many countries, with
the expectation of being introduced in
50 countries by 2015. This will reduce
pneumococcal invasive disease by about
4070%depending on prevalent sero-
types and incidence of HIV infection.5 In
holoendemic malarial areas, BM caused by
nontyphoidal salmonellae species waxed
and then waned over the past decade. In
some areas, this followed the mass intro-
duction of bed nets, indoor spraying and
the change from a failing first line antima-
larial treatment regimen to effective artem-
esinin-based combination therapy.5
DIAGNOSIS
Examination of cerebrospinal fluid
(CSF) is the gold standard diagnostic test in
BM. In many resource poor settings, despite
lack of laboratory support, clinicians should
have a low threshold for doing a lumbar punc-
ture. The appearance and Gram stain of CSF
assist diagnosis. If there is no laboratory, a
multistix urine dipstick test will identify low
glucose, high protein and white cells (a posi-
tive leucocyte esterase patch) in CSF.
GENERAL MANAGEMENT
Children with BM are often managed
with limited resources against a background of
other diseases or ill health that compromise the
outcome even when optimal care is provided.
EMPIRICAL FIRST LINE
TREATMENT AND ANTIBIOTIC
RESISTANCE
The World Health Organization
(WHO) recommends ceftriaxone or cefotax-
ime as first line, empirical, antibiotic therapy
for children with suspected BM. Cefotaxime
is more expensive and requires 8 hourly injec-
tions (ceftriaxone is 12 hourly or once daily).
If cephalosporins are not available, WHO rec-
ommends penicillin or ampicillin and chlo-
ramphenicol in older children, and pencillin
or ampicillin and gentamicin in infants.6
S. pneumoniae susceptibility to peni-
cillin varies worldwide; in Malawi, resist-
ance has been stable at 1618%.5 Falade et al7
reported no penicillin-resistant S. pneumoniae

The ESPID Reports and Reviews of Pediatric Infectious Diseases series topics, authors and contents are chosen and approved
independently by the Editorial Board of ESPID.

The Pediatric Infectious Disease Journal Volume 34, Number 4, April 2015 www.pidj.com|441
Molyneux and Njirammadzi The Pediatric Infectious Disease Journal Volume 34, Number 4, April 2015

TABLE 1. Empirical Antibiotic Treatment for Bacterial Meningitis in Resource Poor Settings

Age Main Causes First Line Treatment Alternative Treatment

<7 days Streptococcus agalactiae Ceftriaxone 50mg/kg/bd Benzylpenicillin

50,000 iu/kg bd
Streptococcus pyogenes Cefotaxime 50mg/kg tds or + Gentamicin 7.5mg/kg od
Ampicillin 50mg/kg bd (smaller doses for prems)
IV/IM for 1421 days IV/IM 1421 days
Enterobacteriae 21 Days for Gram negative 21 Days for Gram negative
Listeria Ampicillin 50mg/kg bd
monocytogenes* IV/IM 1421 days
>7 days, S. agalactiae Ceftriaxone 100mg/kg /day Benzylpenicillin
<2 months 50100,000 iu/kg qds
S. pyogenes Cefotaxime 50mg/kg qds or + Gentamicin 7.5mg/kg od
Ampicillin 50mg/kg qds
Enterobacteriae IV/IM 1421 days IV/IM 1421 days
Nontyphoidal 21 days if Gram negative
salmonellae spp
Staphylococcus aureus Add cloxacillin 50mg/kg tds
(bd if <7 days old)
L. monocytogenes Ampicillin 50mg/kg tds
IV/IM 1421 days
223 months Streptococcus Ceftriaxone 100mg/kg/day or Benzylpenicillin
pneumoniae 100.000 iu/kg qds
Haemophilus influenzae Cefotaxime 50mg/kg qds + Chloramphenicol 25 mg/kg qds
IV/IM 1014 days IV/IM 1014 days
Neisseria meningitidis IV/IM 710 days IV/IM 710 days
Nontyphoidal IV/IM 21 days
salmonellae spp
Enterobacteriae IV/IM 21 days
25 years S. pneumoniae Ceftriaxone 100mg/kg/day or Benzylpenicillin 100.000 iu/kg qds
H. influenzae Cefotaxime 50mg/kg qds + Chloramphenicol 25 mg/kg qds
IV/IM 1014 days IV/IM 1014 days
N. meningitidis IV/IM 710 days IV/IM 710 days
>514 years S. pneumoniae Ceftriaxone 100mg/kg/day or Benzylpenicillin 100.000 iu/kg qds
Cefotaxime 50mg/kg qds + Chloramphenicol 25mg/kg qds
IV/IM 1014 days IV/IM 1014 days
N. meningitidis IV/IM 710 days IV/IM 710 days
>14 years S. pneumoniae Ceftriaxone 2g/day or Benzylpenicillin 100,000 iu/kg qds or
Cefotaxime 50mg/kg qds + chloramphenicol 25mg/kg qds
IV/IM 1014 days IV/IM 1014 days
N. meningitidis IV/IM 710 days IV/IM 710 days
Based on the WHO Pocket Book of Hospital Care for Children.6 Known local susceptibilities must guide first choice of antimicrobial therapy. If the bacterial agent is unidentified use
the longer course of antibiotics. If complications such as a cerebral abscess are suspected or the child is HIV positive a longer course of antibiotics may be needed. A repeat lumbar puncture
may be done after 23 days to assess bacterial erasure and should be repeated if there is clinical deterioration.
*Listeria monocytogenes is uncommon where unpasteurized dairy products and processed meats are unavailable to pregnant women.
Enterobacteriae may be best treated with daily ceftriaxone doses divided and given 12 hourly.
Salmonella meningitis requires prolonged treatment of 46 weeks of antibiotics usually ceftriaxone and ciprofloxacin. A repeat lumbar puncture at the end of treatment is necessary if
there is any doubt about complete infection eradication.
Tds indicates 8 hourly; qds, 6 hourly; bd, twice daily; od, once daily.

isolates in 2009 in Nigeria, and a Ugandan
report showed no full resistance, but 83%
intermediate penicillin resistance.8 Hib is
resistant to chloramphenicol and to ampicillin
in most countries. Nontyphoidal salmonellae
species have become resistant to chloram-
phenicol, cotrimoxazole and ampicillin, leav-
ing the options of ciprofloxacin and/or ceftri-
axone. Table1 shows the common causes of
bacterial meningitis in different age groups
and recommended treatment schedules.
In the non-neonatal group, S. pneumo-
niae is the most common etiological agent,
and if penicillin susceptibility is unknown
a third generation cephalosporin should be
given. Empirical treatment can start with a
cephalosporin and change to an appropri-
ate narrow-spectrum antibiotic if and when
the cause is identified. In Malawi, more
neonatal cases were effectively treated by
ceftriaxone than by penicillin + gentamicin
(99.1% vs. 91.8%; P = 0.006), especially for
Gram-negative isolates (95.1% vs. 86.0%;
P = 0.012).9 Amikacin or parentral ciproflox-
acin are effective for many Gram-negative
bacterial infections (including ESBL), and
can be added for Gram-negative bacteria
when a third generation cephalosporin fails.
DURATION OF ANTIBIOTIC
THERAPY
A large multicountry study (n = 1004)
in resource poor settings compared the out-
come of 5 versus 10 days of ceftriaxone for
BM caused by one of the 3 most common
etiological agents, S. pneumoniae, Neisse-
ria meningitidis and Hib.10 Randomization
was on day 5 and only in stable patients with
no complications. Children receiving 5 days
of antibiotic therapy had a similar outcome
to those who received 10 days of treatment
(60.4% vs. 60.8% survival without sequelae,
26% vs. 27.2% with sequelae).
ADJUVANT TREATMENT
Dexamethasone
Corticosteroids as adjuvant treatment
in BM remain controversial. In a large study,
in African children dexamethasone conferred
no benefit.11 A Cochrane review of adjuvant
steroid therapy found no benefit to outcome
in poorly resourced centers.12
Glycerol
Glycerol has been used to reduce
intracranial pressure. A multicountry South
American study reported encouraging
results; when severe neurological sequelae

442 | www.pidj.com 2015 Wolters Kluwer Health, Inc. All rights reserved.
The Pediatric Infectious Disease Journal Volume 34, Number 4, April 2015 Prevention and Treatment of Bacterial Meningitis
and death were combined, glycerol was bene-
ficial compared with placebo (OR: 0.44; 95%
CI: 0.250.76; P = 0.003).13 In a Malawian
study in which paracetamol and glycerol
were the active adjuvant therapies, there was
no benefit or harm by adding glycerol or par-
acetamol to standard antibiotic therapy.14
SUPPORTIVE CARE
Supportive care is critical and the
importance of good nursing care and monitor-
ing cannot be over-emphasized. Fluids should
be monitored, seizures controlled, adequate
calorie intake ensured and serum glucose and
electrolytes kept within normal limits.
A Cochrane review found no evidence
for fluid restriction and some evidence to
support maintenance intravenous fluids in the
first 48 hours in settings with high mortality
rates and late presentations.15 Where children
present early and mortality is lower, evidence
is insufficient to guide practice.
Seizures must be controlled promptly.
WHO recommends rectal diazepam and/or
paraldehyde followed by phenobarbitone if
convulsions continue. Intractable seizures are
difficult to manage without mechanical ven-
tilator support and loading doses of anticon-
vulsant drugs such as phenobarbitone have
to be repeated despite the risk of respiratory
failure. Neonatal seizures are usually man-
aged with phenobarbitone.
ANAEMIA AND MALNUTRITION
Anemia and malnutrition are common
comorbidities. Roine et al16 found that cor-
recting anemia (less than 8g/dL) with a blood
transfusion reduced mortality in BM to 23%
from 39% without transfusion (P = 0.003).
Also, the odds for death increased by 1.98
in mild, 2.55 in moderate and 5.85 in severe
malnutrition.
PROGNOSIS
Case fatality rate is as high as 37%
depending on the cause, age and other cofac-
tors.13 The prognosis is worse in infants, in
children with low CSF white cell counts or
low glucose, low blood pressure, anemia,
persistent convulsions and those who arrive
2015 Wolters Kluwer Health, Inc. All rights reserved.
late or in coma. To these are added malnutri-
tion and immunosuppression.
COMPLICATIONS
Acute complications other than those
mentioned already include subdural empyema
or intracranial abscess. If fever does not settle
an ultrasound scan of the head should be done
in children with an open fontanelle. Large sub-
dural collections and intracranial abscesses can
be drained trans-fontanelle by experienced per-
sonnel. Antibiotic therapy should be prolonged.
Fever may also be caused by infected injection
or cannula sites, joints or chest infections.
Long-term neurological sequelae are
frequent and often devastating. Some hearing
loss occurs in up to 30% of survivors, espe-
cially following pneumococcal or Salmonella
spp. meningitis. Hydrocephalus may present
after weeks or months. Therefore, all survi-
vors should have their hearing tested and
head size monitored after discharge. Follow-
up should include physical, neurological and
developmental assessments.
FUTURE RESEARCH
Monitoring of incidence and antibiotic
sensitivity must continue to be able to
inform empirical treatment.
Rapid diagnostic tests to identify the
causative agent would reduce the overuse
of broad-spectrum antibiotics.
Research is needed into adjuvant therapy
and seizure control.
Improved neonatal care to reduce infec-
tion rates.
REFERENCES
1. Pentavalent vaccine support. Available at:
www.gavialliance.org/support/nvs/pentavalent.
Accessed October 1, 2014.
2. Delrieu I, Yaro S, Tameklo TA, et al. Emergence
of epidemic Neisseria meningitidis serogroup X
meningitis in Togo and Burkina Faso. PLoS One.
2011;6:e19513.
3. Emergence of W135 Meningococcal Disease - lib-
doc.who.int ... whqlibdoc.who.int/hq/2002/WHO_
CDS_CSR_GAR_2002.1.pdf WHO/CDS/CSR/
GAR/2002.1. Emergence of W135 Meningococcal
Disease. Report of a WHO Consultation Geneva
1718 September 2001. Accessed October 2014.
4. CDC. Updated recommendation from the
Advisory Committee on Immunization Practices
(ACIP) for revaccination of persons at pro-
longed increased risk for meningococcal disease.
MMWR. 2009;58:10421043.
5. Everett DB, Mukaka M, Denis B, et al. Ten years
of surveillance for invasive Streptococcus pneu-
moniae during the era of antiretroviral scale-up
and cotrimoxazole prophylaxis in Malawi. PLoS
One. 2011;6:e17765.
6. Pocket Book of Hospital Care for Children: guidelines
for the management of common childhood illnesses.
2nd edition. 2103. WHO: Geneva. http://apps.who.
int/iris/bitstream/10665/81170/1/9789241548373_
eng.pdf. Accessed July 29, 2014.
7. Falade AG, Lagunju IA, Bakare RA, et al. Invasive
pneumococcal disease in children aged <5 years
admitted to 3 urban hospitals in Ibadan, Nigeria.
Clin Infect Dis. 2009;48(Suppl 2):S190S196.
8. Kisakye A, Makumbi I, Nansera D, et al.
Surveillance for Streptococcus pneumoniae men-
ingitis in children aged <5 years: implications
for immunization in Uganda. Clin Infect Dis.
2009;48(Suppl 2):S153S161.
9. Swann O, Everett DB, Furyk JS, et al. Bacterial
meningitis in Malawian infants <2 months of
age: etiology and susceptibility to World Health
Organization first-line antibiotics. Pediatr Infect
Dis J. 2014;33:560565
10. Molyneux E, Nizami SQ, Saha S, et al; CSF 5
Study Group. A double blind randomised study
comparing 5 vs 10 days of ceftriaxone therapy
for bacterial meningitis in children. The Lancet.
2011; 377:18371845.
11. Molyneux EM, Walsh AL, Forsyth H, et al.
Dexamethasone treatment in childhood bacterial
meningitis in Malawi: a randomised controlled
trial. Lancet. 2002;360:211218.
12. Brouwer MC, McIntyre P, Prasad K, et al.
Corticosteroids for acute bacterial meningitis.
Cochrane Database Syst Rev. 2013;6:CD004405.
13. Peltola H, Roine I, Fernndez J, et al. Adjuvant
glycerol and/or dexamethasone to improve the
outcomes of childhood bacterial meningitis: a
prospective, randomized, double-blind, placebo-
controlled trial. Clin Infect Dis. 2007;45:
12771286.
14. Molyneux EM, Kawaza K, Phiri A, et al. Glycerol
and acetaminophen as adjuvant therapy did
not affect the outcome of bacterial meningi-
tis in Malawian children. Pediatr Infect Dis J.
2014;33:214216.
15. Maconochie IK, Bhaumik S. Fluid therapy for
acute bacterial meningitis. Cochrane Database
Syst Rev. 2014;5:CD004786.
16. Roine I, Weisstaub G, Peltola H; LatAm
Bacterial Meningitis Study Group. Influence
of malnutrition on the course of childhood
bacterial meningitis. Pediatr Infect Dis J.
2010;29:122125.
www.pidj.com | 443